The Valley Desk

NCT05870748 · Interventional trial

REFRaME-O1: A Study to Investigate the Efficacy and Safety of Luveltamab Tazevibulin Versus Investigator's Choice (IC) Chemotherapy in Women With Ovarian Cancer (Including Fallopian Tube or Primary Peritoneal Cancers) Expressing FOLR1

Overall registry status Terminated

Phase 2 · Phase 3

Conditions Epithelial Ovarian Cancer, Fallopian Tube Cancer, Ovarian Cancer, Platinum-resistant Ovarian Cancer, Primary Peritoneal Cancer

Delaware Valley sites

First posted

Registry updated

Added to the directory

View this study on ClinicalTrials.gov